Letter from the Editor

Dear Reader,

At ECTRIMS this year in Stockholm, about 7,000 MS specialists, neurologists, researchers, healthcare professionals gathered to present new data and exchange ideas and experiences in elucidating causes and mechanisms of MS, the genetics of this disease, new diagnostic criteria and methods, the broadening spectrum of related CNS immune disorders (NMOSD), advances in MR imaging, and fluid phase biomarkers. As always management issues were discussed extensively and data from clinical trials of new drugs were presented.

This summary attempts to identify and review the highlights of the congress.
I hope you will find this interesting reading.

Best wishes

Hans-Peter Hartung

Biography

Prof. Hartung has been Chair of the Department of Neurology at Hein-rich-Heine-University in Düsseldorf since 2001. He is also Director of the Center of Neuropsychiatry and the Department of Conservative Medicine at University Hospital Düsseldorf.
He studied medicine at the Universities of Düsseldorf, Glasgow, Oxford, and London. After graduation he served an immunology fellowship at the University of Mainz.
Prof. Hartung’s clinical and translational research interests are in the field of basic and clinical neuroimmunology and in particular multiple sclerosis and immune neuropathies. He has been involved as steering committee member in multiple clinical trials of new drugs for the treatment of multiple sclerosis, Guillain-Barre syndrome, and chronic inflammatory demyelinating polyneuropathy.
Prof. Hartung is a former President of ECTRIMS.

Conflict of Interest Statement:Hans-Peter Hartung has received fees for consulting, speaking, and serving on steering committees from Bayer Healthcare, Biogen, GeNeuro, MedImmune, Merck, Novartis, Opexa, Receptos Celgene, Roche, Sanofi Genzyme, CSL Behring, Octapharma, and Teva, with approval by the Rector of Heinrich-Heine-University.



Posted on 8 November 201922 March 2021